Annexon: Accelerating Immunotherapy Platform with Multiple Milestones in 2026
ByAinvest
Monday, Jan 12, 2026 7:10 am ET1min read
ANNX--
Annexon is advancing its targeted immunotherapy platform for neuroinflammatory diseases with multiple registrational milestones in 2026. The company has filed a MAA for Tanruprubart, aiming to be the first fast-acting therapy for Guillain-Barré Syndrome. Vonaprument Phase 3 topline data for dry AMD with geographic atrophy is expected in H2 2026, and proof-of-concept data for ANX1502, an oral C1 inhibitor for autoimmune disease, is also expected in 2026. Annexon has a strong financial position, funding operations into late 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet